论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Ren L, Yu Y
Received 16 October 2017
Accepted for publication 18 December 2017
Published 25 January 2018 Volume 2018:14 Pages 179—187
DOI https://doi.org/10.2147/TCRM.S154226
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Hoa Le
Peer reviewer comments 3
Editor who approved publication: Professor Deyun Wang
Abstract: Pancreatic ductal adenocarcinoma (PDAC) remains a very challenging
malignancy with late presentation, metastatic potential, chemoresistance, and
poor prognosis. Therefore, there is an urgent need for novel diagnostic and
prognostic biomarkers. miRNAs are small noncoding RNAs that regulate the
expression of multitude number of genes. Aberrant expression of miRNAs has been
linked to the development of various malignancies, including PDAC. A series of
miRNAs have been defined as holding promise for early diagnostics, as indicators
of therapy resistance, and even as markers for prognosis in PDAC patients. In
this review, we summarize the current knowledge on the role of miRNAs in
diagnosis, chemoresistance, and prognosis in PDAC patients.
Keywords: pancreatic
ductal adenocarcinoma, miRNA, diagnosis, prognosis, chemoresistance